Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Next Previous
X
Search
Trial Profile

A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorinostat (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ZOLINZA

    • Most Recent Events

    • 13 Apr 2016 Status changed from not yet recruiting to discontinued because they had collected data of a total of 19 patients for an interim analysis, but there are less than 7 responses out of the initial 19 patients
    • 02 Jan 2013 Planned initiation date changed from 1 Apr 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 23 Apr 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top